ClinicalTrials.gg

Program

ZE94-0605

A development code.

Its studies are mostly in Neoplasm Metastasis, led by Eilean Therapeutics.

Furthest: phase 1, since Mar 27, 20261 company-led study, 1 open or runningNext primary completion: Jan 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eilean Therapeutics11 open or runningphase 1since Mar 27, 2026Mar 27, 2026Jan 2028phase 1 · NCT07524140

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 27, 2026First study: phase 1 study in Neoplasm MetastasisFirst studyNCT07524140 · 60 planned · Australia, Uzbekistan

Ahead

  1. Jan 2028Primary completion: phase 1 study in Neoplasm MetastasisNCT07524140

TargetBeta

CDK2 →read by rule
“ZE94-0605 is an oral, selective cyclin-dependent kinase 2 (CDK2) inhibitor.”study text, by rule · the study

Other programs on CDK2

ProgramCompanyFurthest phaseStudies
culmerciclibSino Biopharmaceuticalphase 311
CDK2 Inhibitor INCB123667ruleIncytephase 37
tegtociclibPfizerphase 24
vustanaciclibregor-pharmaceuticals-incphase 23
CDK2 Inhibitor AVZO-021ruleavenzo-therapeutics-incphase 22
CDK2 Inhibitor ECI830Novartisphase 21
CDK2 Degrader BG-75098ruleBeOne Medicinesphase 11
CG-7321rulechengdu-cynogen-bio-pharmaceutical-tech-co-ltdphase 11
nkt5097 cdk2rulenikang-therapeutics-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07524140Neoplasm Metastasis · Australia, Uzbekistan1RecruitingJan 202860

How it is read

Names in the registry

  • “ZE94-0605”, 1 entry

Codes read as this program: ZE940605.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.